


bsm-61025R**[Primary Antibody]****5HT2C Receptor Recombinant Rabbit mAb****Bioss**
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

— DATASHEET —**Host:** Rabbit**Isotype:** IgG**Clonality:** Recombinant**CloneNo.:** 7D11**GeneID:** 3358**SWISS:** P28335**Target:** 5HT2C Receptor**Immunogen:** A synthesized peptide derived from human 5 HT2C: 406-458.**Purification:** affinity purified by Protein A**Storage:** 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.**Background:** Serotonin (5-hydroxytryptamine, 5-HT), a neurotransmitter, elicits a wide array of physiological effects by binding to several receptor subtypes, including the 5-HT2 family of seven-transmembrane-spanning, G-protein-coupled receptors, which activate phospholipase C and D signaling pathways. This gene encodes the 2C subtype of serotonin receptor and its mRNA is subject to multiple RNA editing events, where genomically encoded adenosine residues are converted to inosines. RNA editing is predicted to alter amino acids within the second intracellular loop of the 5-HT2C receptor and generate receptor isoforms that differ in their ability to interact with G proteins and the activation of phospholipase C and D signaling cascades, thus modulating serotonergic neurotransmission in the central nervous system. Studies in humans have reported abnormalities in patterns of 5-HT2C editing in depressed suicide victims. [provided by RefSeq, Jul 2008].**Applications:** WB (1:500-2000)**Reactivity:** Human (predicted: Mouse, Rat)**Predicted MW.:** 52**Subcellular Location:** Cell membrane**— VALIDATION IMAGES —**

25 ug total protein per lane of various lysates (see on figure) probed with 5HT2C Receptor monoclonal antibody, unconjugated (bsm-61025R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.